Biotech Company Hemostemix Plans Massive Revenue Expansion to $144 Million – Per Month!

Collaboration with the Government of Puerto Rico

Just in time for the launch of its new production facility for its patented autologous blood-based stem cell therapy in Puerto Rico, Canadian biotech company Hemostemix (TSXV:HEM; FRA:2VF0) will be presenting at two investor conferences in Puerto Rico this week. The Sequire Investor Summit on January 22 and 23 at the Condado Vanderbilt Hotel is expected to attract more than 1,500 institutional and high-net-worth investors, including family office investors from around the world. Subsequently, Hemostemix’s partner, CytoImmune, will host a meeting with selected investors on January 24 at CytoImmune’s state-of-the-art facility in San Juan, Puerto Rico.

During his presentations, Hemostemix’s CEO Thomas Smeenk will particularly focus on the partnership with CytoImmune and explain the cash flow targets the partners aim to achieve in the coming years. Together, the partners plan to expand the initial production volume by more than a hundredfold. According to Smeenk, Hemostemix plans to increase revenue from an initial $12 million per year to $144 million per month through full automation of processes. Hemostemix’s ACP treatment not only prevents amputations and saves lives but also improves quality of life and enables the healthcare system to save 80% of care costs over a five-year period.

Collaboration with the Government of Puerto Rico

Hemostemix, CytoImmune, and the Government of Puerto Rico plan to work with the island’s cardiologists, vascular surgeons, thoracic surgeons, and neurosurgeons to treat patients with no treatment options who suffer from the following conditions: 1. vascular dementia; 2. peripheral arterial disease; 3. chronic limb-threatening ischemia; 4. ischemic cardiomyopathy; 5. non-ischemic cardiomyopathy; 6. angina.

The Puerto Rico location offers extraordinarily favorable conditions for Hemostemix, as the Puerto Rican ACT 60 program provides for a 50% cash reimbursement of R expenses.

Meanwhile, Hemostemix intends to continue gathering patient data to prove that ACP remains safe, statistically effective, and clinically relevant to obtain FDA approval.

hemo1-GOLDINVEST — Figure 1: Hemostemix is immediately increasing production.

Keywords

Disclaimer

I. Information Function and Disclaimer: GOLDINVEST Consulting GmbH offers editors, agencies, and companies the opportunity to publish comments, analyses, and news on www.goldinvest.de. The content serves exclusively for general information and does not replace individual, professional investment advice. It does not constitute financial analyses or sales offers, nor is it a solicitation to buy or sell securities. Decisions made based on the published information are entirely at your own risk. No contractual relationship arises between GOLDINVEST Consulting GmbH and the readers or users, as our information relates exclusively to the company and not to personal investment decisions.

II. Risk Disclosure: The acquisition of securities involves high risks, which can lead to the total loss of the capital invested. Despite careful research, GOLDINVEST Consulting GmbH and its authors assume no liability for financial losses or for the content’s guarantee regarding timeliness, accuracy, appropriateness, and completeness of the published information. Please also note our further terms of use.

III. Conflicts of Interest: In accordance with §34b WpHG and §48f para. 5 BörseG (Austria), we point out that GOLDINVEST Consulting GmbH, as well as its partners, clients, or employees, hold shares in the aforementioned companies. Furthermore, a consulting or other service agreement exists between these companies and GOLDINVEST Consulting GmbH, and it is possible that GOLDINVEST Consulting GmbH may buy or sell shares of these companies at any time. These circumstances can lead to conflicts of interest, as the aforementioned companies compensate GOLDINVEST Consulting GmbH for its reporting.